|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ImmunoGen, Inc., Manufacturing
| | | Phone: | (781) 769-4242 | Fax: | (781) 255-1489 | Year Established: | 1981 | Ticker: | IMGN | Exchange: | NASDAQ | Main Contact: | Blaine McKee, Executive VP & CBO | | Other Contacts: | Mark J. Enyedy, President & CEO Eric Guempel, VP, Product Strategy & Program Management Theresa Wingrove, Ph.D., VP, RA Godfrey Amphlett, Ph.D., VP, Process and Analytical Development Robert J. Lutz, Ph.D., VP, Translational Research and Development James O'Leary, M.D., VP & CMO Craig Barrows, VP, General Counsel & Secretary Richard J. Gregory, Ph.D., Executive VP, Research CSO James O'Leary, MD, VP & CMO Charles Morris, M.B., Ch.B., M.R.C.P., Executive VP & Chief Development Officer
| | Company Description | ImmunoGen develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies. The Company’s proprietary Targeted Antibody PayloadTM (TAP) technology consists of ImmunoGen’s highly potent CKAs, which have been designed specifically for delivery by antibodies to cancer cells, and the Company’s engineered linkers, which direct the activation of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s own programs and its collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. | |
|
|
|
|
|